证券代码：002550 证券简称：千红制药 常州千红生化制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | |-----------------------------|----------------------------------| | | | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（ 请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 汇添富基金 刘闯 | | | 时间 2015 年 6 月 16 日 | | | 地点 公司二楼会议室 | | 上市公司接待人 员姓名 | 郑锋林、丁赛君 | | 投资者关系活动 主要内容介绍 | 公司基本情况的调研。 | | 附件清单（如有） 调研记录 | | | | 日期 2015 年 6 月 16 日 | 千红制药机构调研记录 时间： 2015 年 6 月 16 日 地点：公司二楼会议室 参与调研对象：汇添富基金 刘闯 公司参与人员：郑锋林、丁赛君 签订保密承诺书情况：已签订 记 ...

证券代码：002550 证券简称：千红制药 常州千红生化制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | |-----------------------------|--------------------------------------------------------------------------------| | | | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（ 请文字说明其他活动内容） | | 参与单位名称及 | 平安证券 叶寅；平安证券 谢谦；海通证券 穆运周；天弘基 | | 人员姓名 | 金 郭相博；天弘基金 刘盟盟；广发基金 郑超群；农银汇理 陈 卫国；上投摩根 罗会礼 | | | 时间 2016 年 1 月 12 日 | | | 地点 公司二楼会议室 | | 上市公司接待人 员姓名 | 蒋文群 | | 投资者关系活动 主要内容介绍 | 公司基本情况的调研。 | | 附件清单（如有） 调研记录 | | | ...

证券代码：002550 证券简称：千红制药 常州千红生化制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | |-----------------------------|-------------------------------------------------------------------------------------------------------------------------| | | | | | | | 投资者关系活动 | ■ 特定对象调研 □ 分析师会议 | | 类别 | □ 媒体采访 □ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | ■ 现场参观 | | | □ 其他（ 请文字说明其他活动内容） | | 参与单位名称及 | 东兴证券 胡偌碧；东兴证券 唐子媚；东兴证券 孙一兰；金 | | 人员姓名 | 库资本 黄琳佳；西部证券 帅志红；尚近投资 万朋杰；上海 证券 黄纪青；上海证券 周旭馗；敦和资管 陈颖；山东明泰 | | | 资产 王金龙；山东明泰资产 刘佩虎；中乾投资 吴俊康；银 河证券 霍辰依 | | | | | 时间 ...

证券代码：002550 证券简称：千红制药 编号： ■特定对象调研 □分析师会议 投资者关系活动 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ■其他（电话会议） 常州千红生化制药股份有限公司 投资者关系活动记录表 | --- | --- | |-----------------------------|-------------------------------------------| | 参与单位名称及 | 平安证券 叶寅、魏巍、倪亦道、梁欢、张熙 | | 人员姓名 | | | 时间 2017 | 年 4 月 26 日 | | 地点 | 平安证券电话会议网络 | | 上市公司接待人 员姓名 | 蒋文群、肖爱群、姚毅 | | 投资者关系活动 主要内容介绍 | 公司基本情况的调研。 | | 附件清单（如有） 调研记录 | | | 日期 2017 | 年 4 月 26 日 | 千红制药机构调研记录 时间：2017 年 4 月 26 日 地点：平安证券电话会议网络 参与调研对象：平安证券 叶寅、魏巍、倪亦道、梁欢、张熙 公司参与人员：蒋文群、肖爱群、姚毅 签订保密承诺书情况：未签订 记 ...

证券代码：002550 证券简称：千红制药 常州千红生化制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | |-----------------------------|-------------------------------------| | | | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | ■现场参观 | | | □其他 | | 参与单位名称及 | 渤海证券 王斌、高啸虎、朱海峰、梅健 | | 人员姓名 | | | | 时间 2017 年 5 月 5 日 | | | 地点 公司三楼会议室 | | 上市公司接待人 员姓名 | 姚毅、丁赛君 | | 投资者关系活动 主要内容介绍 | 公司基本情况的调研。 | | 附件清单（如有） 调研记录 | | | | 日期 2017 年 5 月 5 日 | 千红制药机构调研记录 时间：2017 年 5 月 5 日 地点：公司三楼会议室 参与调研对象：渤海证券 王斌、高啸虎、朱海峰、梅健 公司参与人员：姚毅、丁赛君 签订保密承诺 ...

证券代码：002550 证券简称：千红制药 常州千红生化制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | |----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Sales Performance - The main product, Trypsinogen (Yikai), has shown steady growth since 2017, achieving nearly 600 million CNY in sales in 2020 despite the pandemic's impact [3] - The company expects to maintain a good growth trend in 2021, with overall business performance steadily recovering [3] Cost Management - The company has the most complete heparin series supply chain in China, but faces significant cost fluctuations due to environmental pressures and upstream resource integration [4] - The company plans to leverage its subsidiary, Hubei Runhong Biotechnology Co., Ltd., to stabilize the supply and cost of heparin sodium products [4] Product Development - The company has completed the consistency evaluation for Enoxaparin Sodium Injection and is prepared to participate in national procurement [5] - Current production capacity for low molecular weight heparin is sufficient at 50 million doses per year [5] New Drug Research - QHRD107, an oral targeted anti-cancer drug, is currently undergoing Phase I clinical trials at Ruijin Hospital in Shanghai [6] - Multiple new drugs, including QHRD102, QHRD106, and QHRD211, have received clinical approval and are in various stages of clinical trials [7] Export Strategy - The export of heparin raw materials significantly declined in 2020 due to COVID-19, but is expected to recover in 2021 [7] - The company is actively expanding its heparin formulation export business, focusing on markets along the Belt and Road Initiative and pursuing certifications for the US FDA and EU CE [7]

Group 1: Company Products and Market Position - The company's main brand product, Yikai (胰激肽原酶), is unlikely to enter the national procurement directory due to low pricing and difficulties in consistency evaluation [3] - Heparin sodium products are essential clinical anticoagulants, with the company holding a complete domestic heparin series supply chain [4] - The company is actively expanding its heparin formulation export business, focusing on countries along the Belt and Road Initiative, showing significant growth potential [4] Group 2: Raw Material Costs and Supply Chain - The procurement costs of key raw materials, heparin crude and crude pancreatin, are subject to significant fluctuations due to environmental pressures and upstream resource consolidation [4] - The company plans to leverage its subsidiary, Hubei Runhong Biotechnology Co., to stabilize the supply and cost of strategic raw materials [4] Group 3: Marketing and Sales Strategies - An OTC division was established in 2020 to implement AI-driven new retail and multi-channel marketing strategies for the compound digestive enzyme product, Yimei [4] - The marketing strategy includes both online and offline promotion, aiming to enhance brand influence and market competitiveness [4] Group 4: Innovation and R&D Progress - The company has five new drugs that have received clinical approval from CDE, with ongoing or planned Phase I clinical trials [5] - QHRD107 and QHRD110 are currently undergoing Phase I trials in Shanghai and Australia, respectively, with several other innovative drugs at various research stages [5] - To support increasing R&D expenses, the company plans to consider refinancing after new drugs successfully enter Phase II trials [5]

Financial Performance - The company's revenue for Q3 2022 was ¥511,943,232.28, representing a 3.35% increase year-over-year, while the year-to-date revenue reached ¥1,648,829,042.01, up 20.50% compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥66,541,577.71, a decrease of 33.97% year-over-year, with a year-to-date net profit of ¥268,398,353.54, which is an increase of 41.32% compared to the previous year[6]. - Basic earnings per share for Q3 2022 were ¥0.0528, down 34.49% year-over-year, while the year-to-date basic earnings per share were ¥0.2142, an increase of 40.74%[6]. - Total operating revenue for the third quarter reached ¥1,648,829,042.01, an increase of 20.5% compared to ¥1,368,373,802.06 in the same period last year[27]. - Net profit for the quarter was ¥257,198,189.23, representing a 40.0% increase from ¥183,985,974.26 in the previous year[29]. - The total comprehensive income attributable to the parent company was ¥264,805,231.67, an increase from ¥189,898,330.57 in the previous period[32]. - Basic and diluted earnings per share were both ¥0.2142, compared to ¥0.1522 in the previous period[32]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥2,770,648,124.67, a 10.45% increase from the end of the previous year[6]. - The company's total assets increased to ¥2,770,648,124.67, compared to ¥2,508,397,996.17 at the end of the previous period, reflecting a growth of 10.4%[26]. - Total liabilities rose to ¥403,958,664.15, up from ¥390,237,603.01, indicating a 1.8% increase[26]. - Shareholders' equity attributable to the parent company reached ¥2,386,979,711.00, which is a 12.21% increase compared to the end of the previous year[6]. - The company's equity attributable to shareholders reached ¥2,386,979,711.00, a significant increase from ¥2,127,250,479.33, marking a growth of 12.2%[26]. Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥54,760,163.91, reflecting a significant decrease of 875.30% compared to the same period last year[6]. - Cash inflow from operating activities totaled ¥1,680,056,558.66, up from ¥1,486,651,144.16 in the previous period[33]. - The net cash flow from operating activities was -¥54,760,163.91, a decline from a positive cash flow of ¥7,063,071.14 in the previous period[36]. - Cash outflow from investing activities was ¥490,689,449.55, compared to ¥321,211,073.04 in the previous period[36]. - The net cash flow from financing activities was ¥56,975,102.90, a recovery from -¥149,699,278.54 in the previous period[36]. - The company received cash from financing activities totaling ¥600,480,000.00, significantly higher than ¥37,006,125.44 in the previous period[36]. - The cash and cash equivalents at the end of the period were ¥508,855,227.02, down from ¥528,478,815.55 in the previous period[36]. Operational Costs and Expenses - The company reported a 32.94% increase in operating costs year-over-year, primarily due to increased sales during the reporting period[11]. - Total operating costs amounted to ¥1,392,256,770.35, up 15.6% from ¥1,205,103,296.49 year-over-year[27]. - Research and development expenses for the quarter were ¥47,814,735.93, compared to ¥44,031,958.91 in the same period last year, reflecting a 6.3% increase[29]. - Financial expenses showed a significant increase, totaling -¥88,141,450.78, compared to -¥10,969,242.25 in the previous year[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 70,125[15]. - The company has a significant shareholder, Wang Yaofang, holding 19.96% of the shares, totaling 255,402,000 shares[15]. - The top ten shareholders include several individuals and investment funds, with the largest holding being Wang Yaofang[15]. Strategic Initiatives - The company plans to invest approximately 600 million CNY in a new raw material drug production base project in Zhongxiang City, which will be constructed in two phases[19]. - The company is focusing on expanding its product lines, including polysaccharide products and high-end anti-thrombotic drugs in the new production base[19]. - The company is actively pursuing strategic initiatives to enhance its market presence and product offerings[19]. Other Financial Metrics - The company received government compensation of ¥57,556,734.94, contributing to an increase in other income[7]. - The company's short-term borrowings increased by 68.30% compared to the beginning of the period, attributed to the need for operational funds[11]. - The company’s cash flow from investing activities decreased by ¥30,580,620.00 year-over-year, mainly due to increased investments in financial products[11]. - Current assets include cash of 508,855,227.02 CNY and accounts receivable of 470,218,117.45 CNY, showing an increase from the previous period[20]. - Inventory at the end of the reporting period was 494,418,074.88 CNY, up from 400,630,285.02 CNY in the previous period[20]. - The company paid ¥165,298,224.09 in cash to employees, a decrease from ¥189,706,232.14 in the previous period[33]. - The company reported a foreign exchange impact on cash and cash equivalents of ¥50,705,760.95, compared to ¥11,431,322.98 in the previous period[36].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,136,885,809.73, representing a 30.23% increase compared to CNY 873,009,228.40 in the same period last year[30]. - The net profit attributable to shareholders of the listed company reached CNY 201,856,775.83, a significant increase of 126.42% from CNY 89,150,017.83 in the previous year[30]. - The net profit after deducting non-recurring gains and losses was CNY 147,139,049.81, up 79.21% from CNY 82,102,693.65 in the same period last year[30]. - The basic earnings per share increased to CNY 0.1615, reflecting a growth of 125.87% compared to CNY 0.0715 in the previous year[30]. - The total operating revenue for the first half of 2022 reached CNY 1,136,885,809.73, a significant increase from CNY 873,009,228.40 in the first half of 2021, representing a growth of approximately 30.3%[199]. - Total operating costs for the first half of 2022 were CNY 944,293,099.59, compared to CNY 765,111,632.69 in the same period of 2021, indicating an increase of about 23.4%[199]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 2,619,695,951.16, which is a 4.44% increase from CNY 2,508,397,996.17 at the end of the previous year[30]. - Total liabilities increased to CNY 455,078,546.05 from CNY 390,237,603.01, representing a growth of approximately 16.6%[193]. - The current liabilities totaled CNY 334,147,438.60, up from CNY 271,329,018.39, indicating an increase of about 23.1%[199]. - Cash and cash equivalents decreased by 1.83% to CNY 597,186,357.67, constituting 22.80% of total assets[72]. - Accounts receivable increased significantly to CNY 556,479,441.17 from CNY 395,723,389.25, marking a growth of approximately 40.6%[187]. Market and Product Development - The raw material drug series generated revenue of 555 million yuan, up 61.87% year-on-year, while the formulation drug series achieved 579 million yuan, growing by 9.44%[40]. - The company has five new drugs approved for clinical trials, with one undergoing trials abroad showing good tolerability and pharmacokinetic characteristics[40]. - The company completed the consistency evaluation filing for N-acetylheparin calcium injection, which is expected to become a new growth point for future development[40]. - The company operates a dual-market strategy focusing on both domestic and international markets, with a professional marketing team established in multiple countries[41]. - The company is actively developing innovative drugs, with multiple products at various research stages, which will strengthen its core competitiveness[57]. Risk Management and Challenges - The management discussed potential risks and countermeasures in the business operations, which are detailed in the report[7]. - The ongoing risks include the impact of COVID-19 on operations and the potential decline in drug prices due to centralized procurement policies[84]. - Short-term borrowings increased by 101.74%, reflecting a rise in operational financing needs[68]. Environmental and Social Responsibility - The company has a wastewater treatment station and multiple exhaust emission outlets operating normally at both its Jiangdong and Yunhe Road plants[103]. - The company reported no exceedance of pollutant discharge standards at its facilities[103]. - The company has implemented various environmental protection projects, including a biochemical enzyme product industrialization demonstration project and a pollution reduction technology transformation project[106]. - The company donated RMB 1 million and over RMB 5 million worth of anti-epidemic medications to support COVID-19 efforts[112]. - The company maintains a harmonious labor relationship, providing various social insurances and training opportunities for employees[111]. Shareholder and Equity Information - The total shares held by employees in the first phase of the employee stock ownership plan is 5,999,999, representing 0.47% of the company's total equity[93]. - The largest shareholder, Wang Yaofang, holds 191,551,500 shares, representing 19.96% of the total shares[161]. - The company reported a total of 345,685,846 limited sale condition shares held by executives, with specific allocations detailed for each executive[160]. - The company has not engaged in any related party transactions during the reporting period[125]. - The total amount of guarantees approved for subsidiaries during the reporting period is ¥2,000 thousand, with an actual guarantee amount of ¥1,679 thousand[140].